Non-alcoholic fatty liver disease (NAFLD) has become one of the most prominent forms of chronic liver disease worldwide, mirroring the obesity epidemic. Those with the progressive variant of NAFLD, non-alcoholic steatohepatitis (NASH), are at significantly increased risk of morbidity and mortality. There are currently no FDA approved pharmacologic therapies for NASH. 

To address this critical need, TamuroBio first embarked on studies that indicate the reduction of 4-HNE could be beneficial in combating NASH as well as identifying viable paths forward for novel mechanism-based therapies in NASH.  


A novel, multi-pathway NASH therapy

Leading the Way

TamuroBio discovered and developed a therapeutic compound, TB-019, which has a unique mechanism of action. Its high affinity for the harmful lipid peroxidation product 4-HNE reduces 4-HNE levels in tissues thereby reduces lipotoxicity.

Addressing Unmet Needs

Currently there are no FDA approved treatments for NASH. TB-019 has demonstrated effectiveness in preventing and mitigating NASH in several established rodent models. This has been seen through the specific attenuation of hepatic steatosis and histology.

Transforming Lives

In the United States, it is estimated that ~16 million adults are affected by NASH. NASH’s complex pathophysiology includes co-morbidities such as obesity, diabetes, and dyslipidemia.